On January 23, 2018, Dr. Li Yuanchao of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and his party visited Guilin SanLengBio to discuss and promote the triptolide cooperation project.
Dr. Li has been working in Shanghai Institute of Materia Medica since 1991 and has served as the team leader, researcher, and doctoral supervisor of the research group. The main direction is based on the research and development of the active ingredients of Tripterygium wilfordii in immunosuppressants and anti-tumor drugs. They have successively undertaken major projects for the major new drug development projects of the Ministry of Science and Technology: Preclinical research on a new class of drugs “Lei Teng Shu” (LLDT-8); and major projects of the Shanghai Municipal Science and Technology Commission: A potent immunosuppressive agent – Tripterygium wilfordii optimization product new drug development and research.
Since 2000, Guilin SanLengBio has participated in the whole process of bioactive compounds of Tripterygium wilfordii Hook/Lei Gong Teng/Thunder God Vine led by Dr. Li in anti-inflammatory, immune regulation and anti-tumor. And they have yielded a series of fruitful scientific research results in research projects, new drug bases and applied research, and preclinical research. In particular, progress has been made in studies on the anti-tumor effects and mechanisms of triptolide and its derivatives.
In May 2017, Shanghai Pharmaceutical Group Co., Ltd. issued an announcement announcing that the hydroxy triptolide tablet developed in cooperation with the Shanghai Institute of Materia Medica had obtained the clinical trial approval document issued by the State Food and Drug Administration. The drug is a class 1 original chemical used to treat chronic abnormal immune activation of AIDS. Similar researches in both domestic and international are in the stage of clinical exploration, so there are no similar products on the market. As of 2017, the drug has invested a total of RMB 34.5 million in research and development.
During the trip in Guilin SanLengBio, Dr. Li visited the independent high-purity active ingredient purification R&D center, and inspected the raw materials acquisition and sustainable supply capacity of Tripterygium wilfordii and felt good.
Up to now, Guilin SanLengBio has acquired more than 200 tons Tripterygium wilfordii, and raw material acquisition work is still continuing. Triptolide production is expected to exceed 5 kg for the whole year. Guilin SanLengBio has prominent advantages in the active ingredients of Tripterygium wilfordii. Since 1997, it has been engaged in research, development, production and sales of Tripterygium wilfordii active ingredients including triptolide and tripterine. It is the only manufacturer in China that has realized the large-scale production of Tripterygium wilfordii active ingredients. It has a long-term and stable raw material procurement channels, and fully guarantee the stable supply of Tripterygium products; At the same time, it has been continuously exploring and made breakthrough progress in the development of the chemical synthesis production process of Tripterygium products. Guilin SanLengBio has been implemented with domestic and foreign pharmaceutical companies and research institutes that use triptolide in the anticancer field, the treatment of human autoimmune diseases, and animal sterilization. We are making unremitting efforts for human health.
